Today, ZyCal Bioceuticals, Inc announced positive results of the first double-blind, placebo-controlled study evaluating Cyplexinol for alleviating symptoms for patients with osteoarthritis.
According to the study, patients receiving Cyplexinol had a significant decrease in pain and stiffness and a significant increase in quality of life compared to those receiving the placebo. Results from the study were published in the peer-reviewed, April/May 2013 issue of Integrative Medicine: A Clinician’s Journal.
Cyplexinol consists of bone morphogenetic proteins (BMPs), which stimulate bone and cartilage growth and fight inflammation. The naturally-derived, biologically active protein complex Cyplexinol is the active ingredient in ZyCal’s Ostinol, which is currently available as an oral supplement through the company as well as through Chiropractors and Naturopathic physicians without a prescription.
“Using BMPs to rebuild cartilage and down-regulate inflammatory pathways is a new and exciting approach to managing the debilitating symptoms of osteoarthritis,” Richard Garian, DC, CCSP, one of the study investigators and co-authors of the paper stated. “For the first time, using rigorous study methods, we were able to demonstrate significant and measurable improvements in pain relief, functionality and quality of life in patients treated with an oral BMP – complex, Cyplexinol in as little as one week.”
The study consisted of 87 patients with moderate-to-severe osteoarthritis who had joint pain in a weight-bearing joint. Participants received a daily dose of either 150 mg of Cyplexinol or placebo for 12 weeks. Pain, stiffness, and quality of life were the three primary endpoints that were measured using the Western Ontario and McMaster University (WOMAC) Osteoarthritis Index 3.1.
Results showed that at week 12, patients receiving Cyplexinol had an improvement (decrease) in pain by 3.35 points versus 0.35 for patients receiving the placebo, improvement (decrease) in stiffness by 2.95 points versus 0.18, and improvement (increase) in quality of life by 3.12 points versus 0.40 points.
“The ability of bone morphogenetic proteins (BMPs) to stimulate bone and cartilage growth is well-documented in peer-reviewed literature and for decades, orthopedic surgeons have used BMPs intra-operatively to treat patients with bone-healing difficulties,” James Scaffidi, President and CEO of ZyCal Bioceuticals, Inc. said in a statement. “In creating Cyplexinol, the first oral BMP – complex, we are able to bring the benefits of BMPs to the millions of people suffering from debilitating bone and joint conditions.”
Source: ZyCal Bioceuticals, Inc.
Last Updated: 4/10/13; 12:30PM EST